Radiosensitizing potential of gemcitabine (2',2'-difluoro-2' deoxycytidine) within the cell cycle in vitro

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 4, 1998, Pages 875-882

  Latz, Detlev ^a   Fleckenstein, Katharina ^a   Eble, Michael ^a   Blatter, Johannes ^b   Wannenmacher, Michael ^a   Weber, Klaus J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Cell cycle sensitivity; Colon carcinoma; Gemcitabine; Radiochemotherapy

Indexed keywords

GEMCITABINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LEVEL; CHINESE HAMSTER; COLON CARCINOMA; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFECT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION;

ANIMALS; CELL CYCLE; CELL LINE; CELL SURVIVAL; COMBINED MODALITY THERAPY; CRICETINAE; CRICETULUS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0031804603     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00105-9     Document Type: Article

References (34)

1. Hertel L.W., Kroin J.S., Misner J.E. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J. Org. Chem. 53:1988;2406-2409.
2. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., Mineishi S., Tarasoff P., Raber M.N., Plunkett W. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9:1991;491-498.
3. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 38:1990;567-572.
4. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Cellular elimination 2′,2′-difluorodeoxycytidine 5′-triphosphate A mechanism of self potentiation . Cancer Res. 52:1992;533-539.
5. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., Grindsay G.B. Evaluation of antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 50:1990;4417-4422.
6. Huang P., Chubb S., Hertel L.W., Grindsey J.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
7. Xu Y.-Z., Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells Action of 2′,2′-difluorodeoxycytidine . Biochem. Pharmacol. 44:1992;1819-1827.
8. Anderson H., Lund B., Bach F. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer A phase II study . J. Clin. Oncol. 12:1994;1821-1826.
9. Catimel G., Vermorken J.B., Clavel M. A phase II study of gemcitabine (LY 188011) inpatients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 5:1994;543-547.
10. Lund B., Kristjansen P.E.G., Hansen H.H. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat. Rev. 19:1993;45-55.
11. Robertson J.M., Shewach D.S., Lawrence T.S. Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Cancer. 78:1996;674-679.
12. Heinemann B., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmocokinetics and toxicity 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosyl-cytosine. Cancer Res. 48:1988;4024-4031.
13. Lawrence T.S., Chang E.Y., Hahn T.M., Hertel L.W., Shewach D.S. Radiosensitization of pancreatic cancer cell lines by 2′,2′-difluoro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;867-872.
14. Shewach D.S., Hahn T.M., Chang E., Hertel L.W., Lawrence T.S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
15. Baker C.H., Banzon J., Bollinger J.M., Stubbe J., Samano V., Robins J.M., Lippert B., Jarvi E., Resvick R. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates Potent mechanism-based inhibitors of ribonucleotide reductase . J. Med. Chem. 34:1991;1879-1884.
16. Bruso C.E., Shewach D.S., Lawrence T.S. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand repair in human colon cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;1411-1417.
17. Dewey W.C., Humphrey R.M. Increase in radiosensitivity to ionizing radiation related to replacement of thymidine in mammalian cells with 5-bromodeoxyuridine. Radiat. Res. 26:1965;538-553.
18. Iliakis G., Pantelias G., Kurtzman S. Mechanism of radiosensitization by halogenated pyrimidines effect of BrdU on cell killing and interphase chromosome breakage in radiation-sensitive cells . Radiat. Res. 125:1991;56-64.
19. Latz D., Trinh M.M., Thompson L.L., Gardiner K., Zhu Y., Bodell W.J., Dewey W.C. The effects of incorporation of bromodeoxyuridine into mammalian DNA on migration patterns of DNA fragments subjected to pulsed-field gel electrophoresis after X irradiation or cutting with a restriction enzyme. Radiat. Res. 138:1994;53-60.
20. Iliakis G. Radiation-induced potentially lethal damage DNA lesions susceptible to fixation . Int. J. Radiat. Oncol. Biol. Phys. 53:1988;541-584.
21. Shewach D.S., Lawrence T.S. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin. Oncol. 22:(Suppl. 11):1995;68-71.
22. Shewach D.S., Lawrence T.S. Radiosensitization of human tumor cell lines with gemcitabine. Semin. Oncol. 23:(Suppl. 10):1996;65-71.
23. Dewey W.C., Miller H.H. X-ray induction of chromatid exchanges in mitotic and G1 Chinese hamster cells pretreated with colcemid. Exp. Cell. Res. 57:1969;63-70.
24. Fertil B., Dertinger H., Courdi A., Malaise E.P. Mean inactivation dose A useful for intercomparison of human cell survival curves . Radiat. Res. 99:1984;73-84.
25. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy The concept of additivity . Int. J. Radiat. Oncol. Biol. Phys. 5:1979;85-91.
26. Blakely E.A., Ngo F.Q.H., Curtis S.B., Tobias C.A. Heavy-ion radiobiology Cellular studies . Adv. Radiat. Biol. 11:1984;295-389.
27. Joiner M.C. Particle beams in radiotherapy. Steel G.G. Basic Clinical Radiobiology. 1993;130-141 Edward Arnold, London.
28. Dewey W.C., Hopwood L.E., Sapareto S.A., Gerweck L.E. Cellular responses to combinationes of hyperthermia and radiation. Radiology. 123:1977;463-474.
29. Gandhi V., Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 50:1990;3675-3680.
30. Ross D.D., Cuddy D.P. Consequences of 2′,2′-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells. Semin. Oncol. 22:(Suppl. 11):1995;26-34.
31. Plunkett W., Huang P., Yi-Zheng X., Heineman V., Grunewald R., Gandhi V. Gemcitabine Metabolism, mechanism of action, and self-potentiation . Semin. Oncol. 22:(Suppl. 11):1995;3-10.
32. Terasima R., Tolmach L.J. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science. 140:1963;490-492.
33. Phillips R.A., Tolmach L.J. Repair of potentially lethal damage in x-irradiated HeLa cells. Radiat. Res. 29:1966;413-432.
34. Iliakis G. The role of DNA strand breaks in ionizing radiation-induced killing of eukaryotic cells. Bioessays. 13:1991;641-648.